Burlington Stores Inc vs Eli Lilly And Co — how do they compare? Burlington Stores Inc trades at $353.4 (market cap $22.59B), while Eli Lilly And Co trades at $1,219.35 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 47.8× Burlington Stores Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.
| BURL | LLY | |
|---|---|---|
Market Cap | $22.59B | $1.08T |
Sector | Consumer Cyclical | Health |
52-Week High | $372.19 | $1.24K |
52-Week Low | $242.43 | $639.43 |
Enterprise Value | $27.71B | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
Burlington Stores (BURL) trades at $353.4, down 4.87% over 24 hours but near its 52-week high, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.01 exceeding expectations. Revenue grew to $10.63 billion in 2025, and the smaller-store strategy is boosting sales productivity. Analyst consensus is overwhelmingly positive, with 94% buy ratings and a $367 price target.
Outlook remains favorable due to consistent earnings outperformance and growth initiatives, though risks include high valuation multiples and competitive retail pressures. The stock offers upside potential aligned with analyst targets, but investors should monitor execution on expansion and margin sustainability.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →